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Abstract 22	
Aminophospholipids (APL), phosphatidylethanolamine (PE) and phosphatidylserine (PS), 23	
can be oxidized upon oxidative stress. Oxidized PE and PS have been detected in clinical samples 24	
of different pathologies and may act as modulators of the inflammatory response. However, few 25	
studies have focused on the effects of oxidized APL (ox-APL) esterified with arachidonic acid, 26	
even though a considerable number of studies have assessed the modulation of the immune system 27	
by oxidized 1-palmitoyl-2-arachidonoyl-sn-3-glycerophosphocholine (OxPAPC). In the present 28	
study, we have used flow cytometry to evaluate the ability of oxidized PAPE (OxPAPE) and PAPS 29	
(OxPAPS) to promote or suppress an inflammatory phenotype on monocytes subsets and myeloid 30	
dendritic cells (mDC). The results indicate that OxPAPE increases the frequency of all monocyte 31	
subpopulations expressing TNF-α, which promotes an inflammatory response. However, immune 32	
cell stimulation with OxPAPE in the presence of LPS results in a decrease of TNF-α expressed by 33	
classical monocytes. Incubation with OxPAPS and LPS induces a decrease in TNF-α produced by 34	
monocytes, and a significant decrease in IL-1β expressed by monocytes and mDC, indicating that 35	
OxPAPS reduce the LPS-induced pro-inflammatory expression in these populations. These results 36	
show the importance of OxPAPE and OxPAPS as modulators of the inflammatory response and 37	
demonstrate their possible contribution to the onset and resolution of human diseases related to 38	
oxidative stress and inflammation. 39	
Keywords: phosphatidylethanolamine, phosphatidylserine, lipid oxidation, lipidomics, flow 40	
cytometry, cytokines  41	
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1β), lipopolysaccharide (LPS), myeloid dendritic cell (mDC), phosphatidylethanolamine (PE), 47	
phosphatidylserine (PS), tumour necrosis factor alpha (TNF-α). 48	
 49	
Introduction 50	
Phosphatidylethanolamine (PE) and phosphatidylserine (PS), which are also termed 51	
aminophospholipids (APL), are components of cell membranes, and display essential signaling 52	
roles in several cellular processes [1]. PE is the second most abundant phospholipid class in cell 53	
membranes and lipoproteins of mammalian organisms, contributing to 20 % of the whole 54	
phospholipid profile [1], whereas PS is a less abundant class that constitutes 2-10% of total 55	
phospholipids [2]. In mammalian cells, PE and PS contribute to membrane properties, such as 56	
membrane curvature, fluidity, and impermeability to water and solutes. They are also mediators of 57	
cell-cell interaction, and provide a membrane anchor for signaling macromolecules [1]. 58	
Upon oxidative stress, unsaturated fatty acyl chains and the polar head groups of APL can 59	
be chemically modified, leading to the formation of oxidized PE and PS derivatives [3–5]. Several 60	
reports have noted the possible interplay between oxidative stress, consequent oxidation of APL, 61	
and inflammation. Oxidized PEs were detected in monocytes treated with IL-4 [6, 7], while 62	
oxidized PS derivatives were found in mice treated with various external stressors, including 63	
hyperoxia [8–10]. Oxidized PE and oxidized PS have also been detected in human pathologies, such 64	
as cystic fibrosis [7] and Alzheimer’s disease [11], which share oxidative stress and inflammation 65	
as common conditions underlying the onset of the disease [12, 13]. 66	
The formation of oxidized derivatives of PE and PS may shift the biological roles of the 67	
native APL towards new functions. A role for oxidized PE in the development of atherosclerosis 68	
was suggested by Zeiseniss et al., who found oxidized 1-palmitoyl-2-linoleoyl-sn-3-69	
glycerophosphoethanolamine (OxPLPE) to be an active thrombogenic factor of oxidized low-70	
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density lipoproteins [14]. More recently, oxidized derivatives of arachidonoyl-PE were highlighted 71	
as the active components which mediate ferroptotic cell death [15]. Recent reports from our group 72	
have also assessed the stimuli mediated by oxidized 1-palmitoyl-2-oleoyl-sn-3-73	
glycerophosphoethanolamine (OxPOPE), OxPLPE, glycated POPE and glycated PLPE in human 74	
peripheral blood immune cells, highlighting the fact that all modified PE could induce a pro-75	
inflammatory response in the tested populations [16, 17].  76	
Oxidized PS has been widely associated with apoptosis; several studies have highlighted its 77	
role as a potent macrophage-activating factor [18–21], which was found to be a phagocytic signal 78	
that, once externalized, mediates the engulfing of cells undergoing intrinsic apoptotic death [22]. 79	
Moreover, oxidized PS was found to induce vascular endothelium growth factor (VEGF) in two 80	
types of human endothelium cells, which suggests a role in the progression and destabilization of 81	
atherosclerotic plaques [23]. Silva et al. reported that oxidized 1-palmitoyl-2-oleoyl-3-sn-3-82	
glycerophosphoserine (OxPOPS), added directly to peripheral blood cells, induced a pro-83	
inflammatory phenotype in monocytes and dendritic cells [24]. 84	
Until now, few studies have focused on the role of PE and PS esterified with arachidonic 85	
acid in the modulation of peripheral blood immune cells. In one report, Morgan et al. observed a 86	
decrease in the production of cytokines in activated monocytes incubated with oxidized 1-stearoyl-87	
2-arachidonoyl-sn-3-glycerophosphoethanolamine (OxSAPE) [25]. In  other studies, oxidized 1-88	
palmitoyl-2-arachidonoyl-sn-3-glycerophosphoserine (OxPAPS) was found to inhibit the 89	
proliferation of T cells isolated from peripheral blood [26], and to antagonize the interaction 90	
between lipopolysaccharide and soluble CD14 [27]. However, the majority of studies concerning 91	
the effects of oxidized phospholipids on immunity used one phosphatidylcholine (PC) bearing an 92	
esterified arachidonoyl chain, namely PAPC, as reviewed by Bochkov and co-authors [28, 29]. 93	
Oxidized PAPC (OxPAPC) was found to be a pro-inflammatory and immunogenic antigen in 94	
apoptotic cells [30], and to activate TLR-4, with the consequent induction of IL-8 [31] and IL-6 95	
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[32]. 1-palmitoyl-2-oxovaleroyl-sn-glycerophosphocholine (POVPC), a short chain oxidation 96	
product from OxPAPC, was found to induce the expression of TNF-α and IL-1β in human 97	
macrophages [33]. Other studies, however, have reported the ability of OxPAPC to antagonize the 98	
interaction of bacterial endotoxins with TLRs and, thus, block their acute inflammatory responses, 99	
including that induced by LPS [27, 34–36]. Knowing this rich interplay between OxPAPC 100	
derivatives and the immune system, we can speculate that oxidized 1-palmitoyl-2-arachidonoyl-sn-101	
glycerophosphoethanolamine (OxPAPE) and OxPAPS species may interact with the immune cell 102	
populations of peripheral blood, and, consequently, mediate the promotion or the resolution of an 103	
inflammatory state. 104	
Because of the lack of knowledge of the biological roles of the PE and PS congeners of 105	
bioactive OxPAPC, in the present study we have obtained OxPAPE and OxPAPS by in vitro 106	
oxidation, characterized them by mass spectrometry (MS), and added them to human peripheral 107	
blood samples. Flow cytometry analysis was then carried out to assess the potential of OxPAPE and 108	
OxPAPS in promoting or inhibiting an inflammatory phenotype in subpopulations of monocytes 109	
and myeloid dendritic cells (mDC). Pro-inflammatory activities were evaluated in peripheral blood 110	
cells stimulated in the absence of LPS, while anti-inflammatory activities were evaluated upon co-111	
incubation of blood cells with oxidized APL (ox-APL) and LPS. We report new insights into the 112	
biological functions of oxidized arachidonoyl-aminophospholipid species in humans, in particular 113	
in the modulation of the inflammatory response mediated by peripheral blood immune cells. 114	
Materials and Methods 115	
Chemicals 116	
PAPE and PAPS were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). 117	
FeCl2 and H2O2 (30%, w/v) used for the Fenton reaction were acquired from Merck (Darmstadt, 118	
Germany). Water was of MilliQ purity filtered through a 0.22 µm filter (Millipore, USA). All 119	
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solvents used were HPLC grade. For cell stimulation, RPMI-1640 medium was purchased from 120	
Gibco (Paisley, Scotland, UK); Brefeldin-A and lipopolysaccharide (LPS) from Escherichia coli 121	
(serotype 055:B5) were from Sigma-Aldrich (St. Louis, MO, USA). For flow cytometry, the 122	
conjugated monoclonal antibodies (mAbs) for HLA-DR V450 (clone L243), CD45 V500-C (clone 123	
2D1), IL-1β PE (clone AS10), CD33 APC (clone P67.6), and CD14 APCH7 (clone MφP9) were 124	
purchased from Becton Dickinson (BD, San Jose, CA, USA); and TNF-α FITC (clone MP6-XT22) 125	
and CD16 PECy7 (clone 3G8) from BD Pharmingen (San Diego,CA, USA). Phosphate-buffered 126	
saline (PBS) was purchased from Gibco, and the permeabilization kit, Intraprep, from Beckman 127	
Coulter (Brea, CA, USA).  128	
Preparation of the ox-APL vesicles 129	
Vesicles of phospholipids were prepared in 5 mM ammonium bicarbonate buffer (pH 7.4). 130	
For each oxidation experiment, 1 mg of phospholipid in chloroform was evaporated to dryness and 131	
reconstituted in 446 µL of buffer. The mixture was shaken mechanically on a vortex mixer for 10 132	
minutes and sonicated for 1 minute. The oxidation was mediated by the hydroxyl radical generated 133	
upon Fenton reaction conditions (Fe2+/H2O2). Hydroxyl radical is a partially reduced oxygen 134	
species, characterized by its high reactivity, and is involved in lipid peroxidation in vivo [37]. The 135	
oxidation was initiated by adding 4 µL of FeCl2 (5 mM stock solution) and 50 µL of H2O2 (500 mM 136	
stock solution) to the phospholipid/buffer mixture, giving final concentrations of 40 µM FeCl2 and 137	
50 mM H2O2 in a final volume of 500 µL. The mixture was incubated at 37 °C and 550 rpm, in the 138	
dark, for 48 hours.  139	
Mass spectrometry 140	
The reactions of oxidation were monitored by electrospray-MS (ESI-MS) in a linear ion trap 141	
mass spectrometer LXQ (ThermoFinnigan, San Jose, CA). An aliquot of 2 µg of each sample was 142	
diluted in methanol (2:400, v/v) and introduced through direct infusion in the mass spectrometer. 143	
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The LXQ linear ion trap mass spectrometer operated in the negative ion mode. Data acquisition and 144	
analysis were performed using the Xcalibur Data System (V2.1, Thermo Fisher Scientific, USA). 145	
The ESI-MS spectra of the oxidation reactions are available online as supplementary information. 146	
Samples 147	
A total of 6 peripheral blood (PB) samples from healthy adult subjects (1 male and 5 148	
females; mean age: 47.4 ± 7.5 years old) were collected in heparin. Informed consent, in accordance 149	
with the local ethics committee, was obtained from all the individuals enrolled in this study. 150	
In vitro stimulation of cytokine production by mDCs and monocytes 151	
For each individual under study, we prepared 10 tubes with 500 µL of PB previously diluted 152	
1:1 (v/v) in RPMI 1640 complete culture medium, supplemented with 2 mM l-glutamine. PB 153	
immune cells were then subjected to 10 different experimental conditions: no stimulation (negative 154	
control), stimulation with LPS (positive control), stimulation with each one of the following native 155	
or modified phospholipids (PAPE, PAPS, OxPAPE, and OxPAPS), and stimulation with those 156	
same phospholipids in the presence of LPS (PAPE+LPS, PAPS+LPS, OxPAPE+LPS, and 157	
OxPAPS+LPS). For this, we added Brefeldin A (10 µg/mL) from Penicillium brefeldiamun (to 158	
prevent the release of de novo produced cytokines outside the cells) to all tubes, 100 ng/mL of LPS 159	
and/or 20 µg/mL of phospholipids, to the corresponding stimulated tube. The samples were then 160	
incubated at 37 °C, in a sterile environment with 5% CO2 humidified atmosphere, for 6 hours. 161	
Flow cytometry analysis of cytokine production 162	
After the incubation period, the PB samples under the different experimental conditions 163	
were stained with mAbs for membrane antigens (HLA-DR, CD45, CD16, CD33, and CD14), 164	
incubated for 10 min at room temperature in the dark, washed once with 2 mL of PBS and 165	
centrifuged for 5 min at 540g. The supernatant was discarded; cells were then fixed and 166	
permeabilized with the Intrapep kit according to manufacturer’s instructions, and stained with 167	
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mAbs for intracellular cytokines (TNF-α and IL-1β). The samples were then incubated for 15 min at 168	
room temperature in the dark, washed twice with 2 mL of PBS, resuspended in 500 µL of PBS, and 169	
immediately analysed in the flow cytometer. 170	
Data acquisition and analysis 171	
Data acquisition was performed with a FACSCanto™II (BD) flow cytometer using 172	
FACSDiva software (v6.1.2; BD). The whole sample from each tube was acquired and stored, 173	
corresponding to a number of events always above 0.5x10.6 For data analysis, Infinicyt software 174	
(version 1.7; Cytognos SL, Salamanca, Spain) was used. 175	
Immunophenotypic identification of classical, intermediate, and non-classical monocytes, 176	
and mDCs 177	
The mAb panel used allowed the identification of classical, intermediate, and non-classical 178	
monocytes, and mDCs, as follows: classical monocytes express high levels of CD14 in the absence 179	
of CD16, together with high expression of CD33 and HLA-DR; intermediate monocytes present 180	
high expression of CD14 together with an increased expression of CD16, and lower levels of CD33 181	
compared to classical monocytes; finally, non-classical monocytes show CD16 positivity with a 182	
decreased expression of CD14, the highest expression of CD45 and the lowest CD33 levels among 183	
the three monocyte subpopulations, whereas HLA-DR expression is between that of classical and 184	
intermediate monocytes. mDC are characterized by lower side-scatter light dispersion properties 185	
and CD45 expression compared to monocytes, and high expression of CD33 and HLA-DR in the 186	
absence of CD14 and CD16. 187	
Statistical methods 188	
Mean values and standard deviations, as well as median values and range, were calculated 189	
for each variable under study by using the SPSS software program (SPSS 17.0, Chicago, USA). The 190	
statistical significance of the differences observed between groups was evaluated using the paired-191	
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sample Wilcoxon test. Differences between groups were considered statistically significant when p-192	
value <0.05. 193	
Results 194	
The ability of the modified APL derivatives OxPAPE and OxPAPS to induce or inhibit the 195	
production of cytokines (TNF-α and IL-1β) was evaluated in three subpopulations of peripheral 196	
blood monocytes (classical, intermediate and non-classical) and in mDC. To evaluate the effect of 197	
the modified APL, both the frequency of cytokine-producing cells, expressed as a percentage, and 198	
the total amount of cytokines produced per cell, expressed as mean fluorescence intensity (MFI), 199	
were determined for each tested condition. 200	
We studied the production of the cytokines TNF-α and IL-1β by classical, intermediate and 201	
non-classical monocytes and mDC in peripheral blood at basal level (negative control), upon 202	
stimulation with LPS (positive control), and after incubation with ox-APL (OxPAPE, OxPAPS) and 203	
non-modified APL (PAPE, PAPS). The results obtained from the incubation of peripheral blood 204	
with the different non-modified or ox-APL were compared with negative control, with the aim of 205	
seeing if these species would be able to induce an increase in either the frequency or amount of pro-206	
inflammatory cytokines production by monocytes and mDC. Non-modified and ox-APL were also 207	
incubated with peripheral blood in the presence of LPS, to evaluate their ability to influence the 208	
immune cell function in an inflammatory environment. The results given by the co-incubation of 209	
blood with LPS and APL or ox-APL were compared with a positive control (LPS-treated blood) to 210	
see if these species could decrease the frequency or amount of cytokine production by monocytes 211	
and mDC. This allowed the assessment of the modulatory activities of the oxidized phospholipids 212	
studied, based on the different interactions of the APL with the antigen-presenting cells, with 213	
emphasis on the effect of oxidation and of the chemistry of the polar head group. The amount of ox-214	
APL mixture chosen for each experiment (20 µg) has already been optimized in other studies from 215	
our group [16, 17]. 216	
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Identification of the oxidized species by direct infusion ESI-MS. 217	
Analysis by direct infusion ESI-MS in negative ion mode was performed to identify the oxidized 218	
species present in the OxPAPE and OxPAPS mixtures obtained after oxidation of hydroxyl radical 219	
generated by the Fenton reaction. Comparing the ESI MS spectra of the PAPE and PAPS 220	
standards before and after the Fenton reaction (Supplementary Figures 3 and 4, respectively), we 221	
were able to observe significant changes. For both PAPE and PAPS, new ions appeared at higher 222	
m/z values then the [M-H]- ions of the nonmodified species, and were identified as long chain 223	
oxidation products ([M + nO]-, n = 1 7). The oxidation products identified in the OxPAPE and 224	
OxPAPS mixtures are summarized in Supplementary Table 3: the most abundant OxPAPE species 225	
was PAPE (+2O-4Da), followed by the hydroxy (PAPE+O) and hydroxy-hydroperoxy (PAPE+3O) 226	
derivatives. In the case of PAPS oxidation (Supplementary Figure 4; Table 3) the most abundant 227	
OxPAPS species were PAPS +4O,correspondent mainly to dihydroperoxy derivative, followed by 228	
the PAPS+30 (correspondent mainly to hydroxy-hydroperoxy derivative) and the polar head 229	
oxidation product  bearing a terminal acetic acid (POPS-29Da) [4]. . 230	
 231	
Evaluation of the activity of OxPAPE in monocytes and dendritic cells. 232	
The frequency of cytokine-producing cells and the amount of cytokines produced per cell 233	
(measured as MFI) were tested in cells from peripheral blood characterized by basal immune 234	
parameters (negative control) and in peripheral blood after incubation with ox-APL. We did not 235	
observe any significant increase in the frequency of monocytes and mDC producing TNF-α and IL-236	
1β, after stimulation with OxPAPS compared with negative control. Also, incubation with OxPAPS 237	
compared with negative control did not significantly affect the amount of TNF-α or IL-1β produced 238	
per cell, measured as MFI, in any of the populations tested (Table 1; Figure 1). Significant 239	
variations were only observed after incubation with OxPAPE. In this case, we saw a significant 240	
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increase in the frequency of cells expressing TNF-α, in all the monocyte subpopulations, after 241	
stimulation with OxPAPE, compared with negative control (Table 1; Figure 1). A statistically 242	
significant increase was also noted for classical monocytes expressing IL-1β after stimulation with 243	
OxPAPE compared with negative control (Table 1; Figure 1). Stimulation with OxPAPE did not 244	
induce any significant increase in the frequency of intermediate monocytes, non-classical 245	
monocytes expressing IL-1β, or in the frequency of mDC expressing TNF-α and IL-1β, when 246	
compared with negative control. Stimulation with OxPAPE did not lead to significant changes in 247	
the amount of TNF-α or IL-1β produced per cell, measured as MFI, in any of the tested cell 248	
populations. With the native PAPE and PAPS, we found a significant increase in the frequency of 249	
classical monocytes and intermediate monocytes expressing TNF-α after stimulation with PAPE 250	
compared with negative control (Supplementary Table 1; Supplementary Figure 1). However, after 251	
stimulation with PAPS, we found a significant increase in the frequency of classical monocytes and 252	
intermediate monocytes expressing TNF-α and IL-1β, when compared with negative control 253	
(Supplementary Table 1, Supplementary Figure 1). Though not reaching statistically significant 254	
levels, PAPS also exhibits a tendency to increase the percentage of cells producing TNF-α and IL-255	
1β in non-classical monocytes and mDC. It is interesting to note that this ability of PAPS to 256	
transversally promote pro-inflammatory cytokine expression in distinct monocyte subsets and mDC 257	
is lost in OxPAPS. 258	
Evaluation of the activity of OxPAPS in monocytes and dendritic cells. 259	
The frequency of cytokine-producing cells and the amount of cytokines produced per cell 260	
were tested in cells from peripheral blood upon LPS-induced acute inflammation (positive control), 261	
and in cells from peripheral blood after incubation with LPS and non-modified or ox-APL. This 262	
allowed us to evaluate whether these species could inhibit the inflammatory stimulus of LPS, i.e. if 263	
they had any anti-inflammatory activity. 264	
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Co-incubation of LPS and OxPAPE did not lead to any significant decrease in the frequency 265	
of monocytes or of mDC producing TNF-α and IL-1β. Considering the amount of cytokines 266	
produced per cell, co-incubation of LPS and OxPAPE led to a statistically significant decrease in 267	
the amount of TNF-α expressed by classical monocytes with respect to positive control, expressed 268	
as MFI (Table 2; Figure 2). However, the amount of IL-1β produced by classical monocytes, and 269	
the amount of TNF-α and IL-1β produced by intermediate monocytes, non-classical monocytes, and 270	
mDC, did not decrease significantly upon treatment with LPS + OxPAPE, against positive control. 271	
We found that the co-incubation of LPS and OxPAPS induced a statistically significant 272	
decrease in the amount of TNF-α produced by classical monocytes and non-classical monocytes, in 273	
comparison with positive control. Incubation of OxPAPS with blood treated with LPS also induced 274	
a significant decrease in the amount of IL-1β expressed by non-classical monocytes and mDC 275	
(Table 2; Figure 2). The amount of TNF-α expressed in intermediate monocytes and mDC, and  the 276	
amount of IL-1β expressed by intermediate monocytes and classical monocytes, did not decrease 277	
significantly when compared with positive control. Moreover, we saw that co-incubation LPS + 278	
OxPAPS, in comparison with positive control, led to a significant decrease in the frequency of 279	
mDC producing TNF-α (Table 2; Figure 2). The frequency of IL-1β-expressing mDC, along with 280	
the frequency of monocytes expressing TNF-α and IL-1β, were not affected by LPS + OxPAPS. In 281	
the case of native PAPE and PAPS, co-incubation of LPS and PAPE did not lead to any significant 282	
decrease either in the frequency of monocytes and mDC producing TNF-α or IL-1β, or in the 283	
amount of cytokines produced per cell (MFI) (Supplementary Figure 2, Supplementary Table 2). 284	
Treatment with LPS+PAPS compared to the positive control, led to a statistically significant 285	
decrease in the amount of TNF-α produced by all the monocytes subpopulations, expressed as MFI 286	
(Supplementary Figure 2, Supplementary Table 2). Interestingly, there is a marked contrast between 287	
the striking inhibitory effect of OxPAPS over TNF-α expression by mDC and the absence of effect 288	
observed for native PAPS.  289	
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Discussion 290	
Oxidized phospholipids are recognized as important players in both the immune response 291	
and the development of various pathologies [29]. With pathologies that are associated with an 292	
increased ROS production, such as Alzheimer’s disease, cystic fibrosis and alcoholic liver disease, 293	
the occurrence of ox-APL could be a potential source of molecules involved in the triggering or in 294	
the resolution of the inflammatory state [38, 11, 7]. With the aim of shedding more light on the 295	
relationship between oxidized arachidonoyl-APL and inflammation, we have used flow cytometry 296	
to obtain new insights into the modulation of peripheral blood immune cells by OxPAPE and 297	
OxPAPS. We have evaluated the influence of OxPAPE and OxPAPS on the frequency of 298	
monocytes and mDC that produce cytokines, and have assessed the quantity of TNF-α and IL-1β 299	
produced by each cell subpopulation. 300	
Among the ox-APL in this study, only OxPAPE induced a pro-inflammatory response after 301	
incubation with immune cells. In this case, the pro-inflammatory action was always due to an 302	
increase in the proportion of monocytes producing TNF-α and IL-1β (classical, intermediate and 303	
non-classical monocytes); no significant effect was observed in the amount of cytokines produced 304	
per monocyte, and no effect was observed on mDC. This suggests that when OxPAPE is generated 305	
in vivo upon oxidative stress, it can promote an inflammatory environment by increasing the 306	
percentage of monocytes that produce pro-inflammatory cytokines. Oxidized PE has already been 307	
highlighted as a pro-inflammatory mediator [16, 17]. However, the effects of OxPAPE on 308	
peripheral blood immune cells have never been studied; this is the first report of the pro-309	
inflammatory activity of OxPAPE as a group of species able to stimulate monocytes in peripheral 310	
blood. 311	
OxPAPE is not the first arachidonoyl phospholipid for which a pro-inflammatory activity 312	
was observed. Walton and co-authors [31] reported that OxPAPC could bind toll-like receptor 4 313	
(TLR4), a known receptor of bacterial endotoxins which activates intracellular signalling pathways 314	
	14	
	
leading to cytokine production. Interestingly, the authors found that the binding of OxPAPC to 315	
TLR4 occurred through a CD14-independent mechanism, promoting the activation of TLR4 316	
receptor. In another report, OxPAPC was seen to stimulate cytokine production in macrophages and 317	
induce acute lung injury through a pathway that included TLR4 and the activation of the TRIF 318	
adaptor protein [32]. It is worth noting that the expression of TLR4 is markedly lower in mDC than 319	
in monocytes [39]. Hence, we suggest that the specific stimulation of OxPAPE could be due to its 320	
activating binding to TLR4. Thus the activation of TLR4 would induce transcriptional factors, such 321	
as NF-κB and AP-1, that ultimately lead to the expression of pro-inflammatory cytokines (TNF-α 322	
and IL-1β) [40, 41]. 323	
Oxidized PS did not show pro-inflammatory effects. This is in agreement with previous 324	
work from our group, where we noted that OxPOPS species did not induce any pro-inflammatory 325	
shift in peripheral blood immune cells [24]. In contrast, OxPAPS reduced the LPS-induced pro-326	
inflammatory phenotype in classical monocytes, non-classical monocytes, and mDC, in the 327	
presence of LPS. In all the immune cell populations studied, OxPAPS decreased the amount of 328	
cytokines produced per cell. This anti-inflammatory effect is in agreement with published works in 329	
which OxPAPC and OxPAPS were found to antagonize the recognition of LPS by the CD14-TLR4 330	
complex at several steps, arbitrating a multi-hit inhibition of the LPS-induced inflammatory 331	
response in monocytes [27]. OxPAPS, in particular, was found to form a covalent complex with 332	
CD14, a co-receptor for TLR4, acting as a competitive inhibitor of the binding between LPS and 333	
TLR4 [27]. In addition, the externalization of oxidized PS on the membrane surface provides a 334	
proven immunosuppressive mechanism leading to cell clearance and resolution of inflammation 335	
[19, 42–44]. In HL60 and Jurkat cells undergoing intrinsic apoptosis, oxidized PS externalized on 336	
the plasma membrane was found to directly participate in the process of cell engulfment mediated 337	
by professional phagocytes [22]. Greenberg et al. [18] highlighted the role of CD36 as the receptor 338	
by which macrophages recognize OxPAPS. Since CD36 is also expressed in monocytes [45] and 339	
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mDC [46], we suggest that the anti-inflammatory effect that we observed for OxPAPS could be due 340	
to the activation of CD36, whose intracellular signalling in monocytes leads to the inactivation of 341	
NF-κB, and to a decreased expression of pro-inflammatory cytokines, such as TNF-α and IL-1β 342	
[47, 48].Several studies have reported that apoptotic cells exposing oxidized PS are capable of 343	
initiating the transduction of signals in mDC that induces the downregulation of various 344	
inflammatory pathways via inhibition of NF-κB and TLRs (reviewed in reference [49]). The 345	
OxPAPS tested in the present study might have activated such anti-inflammatory signaling in 346	
peripheral mDC, thus leading to the decreased production of cytokines per mDC that we observed. 347	
The non-oxidized PAPE and PAPS were also able to induce an inflammatory response in classical 348	
and intermediate monocytes, but this was less than the ox-APL. A similar trend was already 349	
observed for 1,2-dipalmitoyl-3-sn-glycerophosphoethanolamine (DPPE) and PLPE [17]. We also 350	
saw an anti-inflammatory shift induced by PAPS in all monocyte subpopulations, in agreement with 351	
recent studies implicating native PS as an anti-inflammatory factor [50, 51]. However, non-352	
modified APLs are mainly confined in the inner leaflet, where they are kept by the action of specific 353	
flippases [52] and scramblases.[53–57], that hinder PE and PS from the signaling interaction with 354	
other cells. Oxidation of PE and PS is known to induce the externalization of the ox-APL on the 355	
outer leaflet of mammalian cell membranes [19, 25, 43], and, as a consequence, the oxidized PAPE 356	
and PAPS, rather than their native congeners, seem to be involved in signalling events resulting in 357	
the modulation of the immune system, mentioned earlier.  358	
Conclusions 359	
The results of this study clearly demonstrate that oxidized arachidonoyl-APL can modulate 360	
the immune system and the inflammatory response in peripheral blood immune cells. We 361	
emphasized the role of OxPAPE as a promoter of the inflammatory response in circulating immune 362	
cells that is capable  of inducing an increased frequency of TNF-α- and IL-1β-producing 363	
monocytes. In contrast, we found that OxPAPS is an anti-inflammatory agent in peripheral blood 364	
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immune cells treated with the LPS bacterial endotoxin, and is able to downregulate the amount of 365	
cytokines produced per cell in each monocyte subpopulation and in mDC. Peroxidation of PAPE 366	
and PAPS occurs in inflammatory diseases characterized by oxidative stress. Thus, OxPAPE and 367	
OxPAPS can be key players in either the triggering or resolution of the inflammatory state 368	
underlying the onset and the development of such pathologies. For future studies, the information 369	
provided by flow cytometry can be integrated with detailed structural characterization of the 370	
OxPAPE and OxPAPS molecular species detected in clinical samples. This combined approach 371	
could provide a clear relationship between the structure of the ox-APL and its activity on the 372	
immune system, finally allowing the identification and the validation of new biomarkers of 373	
immune-mediated inflammatory diseases. 374	
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Captions 599	
Figure 1. Pro-inflammatory effect of OxPAPE. Frequency of cells producing TNF-α and IL-1β, 600	
among classical (CMo), intermediate (IMo) and non-classical (NCMo) monocytes, and mDC, in the 601	
absence of LPS (negative control) and after incubation with OxPAPE and OxPAPS. Differences 602	
with respect to negative control were considered statistically significant (*) when p < 0.05 (paired-603	
sample Wilcoxon test). %, the percentage of positive cells. 604	
Figure 2. Suppression of the inflammatory effect induced by LPS mediated by OxPAPS. 605	
Frequency of cells producing TNF-α and IL-1β, among classical (CMo), intermediate (IMo) and 606	
non-classical (NCMo) monocytes, and mDC, after stimulation with LPS (positive control), LPS + 607	
OxPAPE, or LPS + OxPAPS (A). Amount of TNF-α and IL-1β produced per cell (measured by 608	
MFI), after stimulation with LPS (positive control), LPS + OxPAPE, or LPS + OxPAPS (B). 609	
Differences with respect to positive control were considered statistically significant (*) when p < 610	
0.05 (paired-sample Wilcoxon test). %, the percentage of positive cells. MFI, mean fluorescence 611	
intensity.  612	
Table 1. Pro-inflammatory effect of OxPAPE. Frequency of cells producing TNF-α and IL-1β, 613	
and amount of cytokine expressed per cell (measured as MFI), among classical (CMo), intermediate 614	
(IMo) and non-classical (NCMo) monocytes, and mDC, under the following culture conditions: in 615	
absence of stimulus (negative control) and after incubation with OxPAPE or OxPAPS. Results are 616	
expressed as a mean ± standard deviation. Differences with respect to negative control were 617	
considered statistically significant (*) when p < 0.05 (paired-sample Wilcoxon test). %, the 618	
percentage of positive cells. MFI, mean fluorescence intensity. 619	
Table 2. Suppression of the inflammatory effect induced by LPS mediated by OxPAPS. 620	
Frequency of cells producing TNF-α and IL-1β, and amount of cytokine expressed per cell 621	
(measured as MFI), among classical (CMo), intermediate (IMo) and non-classical (NCMo) 622	
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monocytes, and mDC, under the following culture conditions: after LPS-induced inflammatory 623	
stimulus (positive control), after incubation with LPS + OxPAPE, or LPS + OxPAPS. Results are 624	
expressed as a mean ± standard deviation. Differences with respect to positive control were 625	
considered statistically (*) significant when p < 0.05 (paired-sample Wilcoxon test). %, the 626	
percentage of positive cells; MFI, mean fluorescence intensity. 627	
 TNF-α IL-1β 
  % MFI % MFI 
CMo LPS 99 ± 0.52 60230 ± 24783 84 ± 11 678 ± 208 
LPS + OxPAPE 100 ± 0.55 40348 ± 10770 * 88 ± 10 541 ± 147 
LPS + OxPAPS 
 
98 ± 1.87 31426 ± 9655 * 75 ± 27.94 471 ± 100 
IMo LPS 100 ± 0.82 114688 ± 37431 95 ± 3.20 1434 ± 915 
LPS + OxPAPE 100 ± 0.00 85979 ± 24198 97 ± 2.97 992 ± 430 
LPS + OxPAPS 
 
100 ± 0.82 77434 ± 30211 87 ± 16.96 918 ± 596 
NCMo LPS 99 ± 1.17 110415 ± 46131 78 ± 19 1040 ± 484 
LPS + OxPAPE 99 ± 0.55 186478 ± 226387 79 ± 10 560 ± 215 
LPS + OxPAPS 
 
98 ± 2.48 69449 ± 20662 * 77 ± 10.39 697 ± 389 * 
mDC LPS 82 ± 12 19392 ± 10727 53 ± 21 418 ± 129 
LPS + OxPAPE 68 ± 16 17388 ± 13001 55 ± 21 381 ± 93 
LPS + OxPAPS 47 ± 12 * 15823 ± 9547 66 ± 22 327 ± 80 * 
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 632	
Figure 1. Pro-inflammatory effect of OxPAPE. Frequency of cells producing TNF-α and IL-1β, 633	
among classical (CMo), intermediate (IMo) and non-classical (NCMo) monocytes, and mDC, in the 634	
absence of LPS (negative control) and after incubation with OxPAPE and OxPAPS. Differences 635	
with respect to negative control were considered statistically significant (*) when p < 0.05 (paired-636	
sample Wilcoxon test). %, the percentage of positive cells.  637	
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 639	
Figure 2. Suppression of the inflammatory effect induced by LPS mediated by OxPAPS. 640	
Frequency of cells producing TNF-α and IL-1β, among classical (CMo), intermediate (IMo) and 641	
non-classical (NCMo) monocytes, and mDC, after stimulation with LPS (positive control), LPS + 642	
OxPAPE, or LPS + OxPAPS (A). Amount of TNF-α and IL-1β produced per cell (measured by 643	
MFI), after stimulation with LPS (positive control), LPS + OxPAPE, or LPS + OxPAPS (B). 644	
Differences with respect to positive control were considered statistically significant (*) when p < 645	
0.05 (paired-sample Wilcoxon test). %, the percentage of positive cells. MFI, mean fluorescence 646	
intensity.   647	
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Table 1. Pro-inflammatory effect of OxPAPE. Frequency of cells producing TNF-α and IL-1β, 648	
and amount of cytokine expressed per cell (measured as MFI), among classical (CMo), intermediate 649	
(IMo) and non-classical (NCMo) monocytes, and mDC, under the following culture conditions: in 650	
absence of stimulus (negative control) and after incubation with OxPAPE or OxPAPS. Results are 651	
expressed as a mean ± standard deviation. Differences with respect to negative control were 652	
considered statistically significant (*) when p < 0.05 (paired-sample Wilcoxon test). %, the 653	
percentage of positive cells. MFI, mean fluorescence intensity. 654	
 TNF-α IL-1β 
  % MFI % MFI 
CMo Negative control 0.81 ± 0.25 5231 ± 2332 0.23 ± 0.15  N/A 
OxPAPE 4.58 ± 2.89 * 3231 ± 1399 2.54 ± 3.43 * 362 ± 36 
OxPAPS 
 
0.95 ± 0.36 6103 ± 2047 0.18 ± 0.06 586 ± 315 
IMo Negative control 0.66 ± 0.43  N/A 4.23 ± 4.15  N/A 
OxPAPE 8.25 ± 5.97 * 3214 ± 1956 7.26 ± 5.15 375 ± 84 
OxPAPS 
 
1.46 ± 1.64  N/A 3.68 ± 4.41 306 ± 25 
NCMo Negative control 0.35 ± 0.25  N/A 1.52 ± 1.61  N/A 
OxPAPE 2.69 ± 3.37 *  N/A 2.26 ± 1.40 336 ± 36 
OxPAPS 
 
0.60 ± 0.99  N/A 2.55 ± 4.68 324 ± 7.07 
mDC Negative control 0.45 ± 0.31  N/A 0.17 ± 0.21  N/A 
OxPAPE 0.58 ± 0.36  N/A 0.33 ± 0.23  N/A 
OxPAPS 0.46 ± 0.68  N/A 0.10 ± 0.08  N/A 
  655	
	27	
	
Table 2. Suppression of the inflammatory effect induced by LPS mediated by OxPAPS. 656	
Frequency of cells producing TNF-α and IL-1β, and amount of cytokine expressed per cell 657	
(measured as MFI), among classical (CMo), intermediate (IMo) and non-classical (NCMo) 658	
monocytes, and mDC, under the following culture conditions: after LPS-induced inflammatory 659	
stimulus (positive control), after incubation with LPS + OxPAPE, or LPS + OxPAPS. Results are 660	
expressed as a mean ± standard deviation. Differences with respect to positive control were 661	
considered statistically (*) significant when p < 0.05 (paired-sample Wilcoxon test). %, the 662	
percentage of positive cells; MFI, mean fluorescence intensity. 663	
 TNF-α IL-1β 
  % MFI % MFI 
CMo LPS 99 ± 0.52 60230 ± 24783 84 ± 11 678 ± 208 
LPS + OxPAPE 100 ± 0.55 40348 ± 10770 * 88 ± 10 541 ± 147 
LPS + OxPAPS 
 
98 ± 1.87 31426 ± 9655 * 75 ± 27.94 471 ± 100 
IMo LPS 100 ± 0.82 114688 ± 37431 95 ± 3.20 1434 ± 915 
LPS + OxPAPE 100 ± 0.00 85979 ± 24198 97 ± 2.97 992 ± 430 
LPS + OxPAPS 
 
100 ± 0.82 77434 ± 30211 87 ± 16.96 918 ± 596 
NCMo LPS 99 ± 1.17 110415 ± 46131 78 ± 19 1040 ± 484 
LPS + OxPAPE 99 ± 0.55 186478 ± 226387 79 ± 10 560 ± 215 
LPS + OxPAPS 
 
98 ± 2.48 69449 ± 20662 * 77 ± 10.39 697 ± 389 * 
mDC LPS 82 ± 12 19392 ± 10727 53 ± 21 418 ± 129 
LPS + OxPAPE 68 ± 16 17388 ± 13001 55 ± 21 381 ± 93 
LPS + OxPAPS 47 ± 12 * 15823 ± 9547 66 ± 22 327 ± 80 * 
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